First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

计划入组 263 人 · 首次发布于 2019 年 8 月 26 日

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

计划入组 420 人 · 首次发布于 2021 年 3 月 23 日

Menin-Inhibitor Targeted Maintenance in AML

计划入组 146 人 · 首次发布于 2026 年 5 月 1 日

Ziftomenib(Komzifti)

C₃₃H₄₂F₃N₉O₂S₂

DOT1L-MLL ineraction inhibitors (leukemia)

mixed lineage leukemia (MLL) interaction inhibitor C20

Kura Oncology

United States

Biomea Fusion

United States

University Of Benin

Nigeria

ASH 2024: Novel Therapies and Strategies Advance Hematologic Cancer Treatment

Kura Oncology's Menin Inhibitor Ziftomenib Receives FDA IND Clearance for Advanced GIST

Ziftomenib Plus Intensive Induction Shows Promise in NPM1-Mutated AML